Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | MMP1 | P03956 | 3/20 | 0.53 |
| ▸ | MMP9 | P14780 | 3/20 | 0.53 |
| ▸ | MMP13 | P45452 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | MMP8 | P22894 | 2/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 2/20 | 0.51 |
| ▸ | FLT4 | P35916 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13866357 | 0.86 | ALOX5 (0.75) | ALOX5MMP2CA2MMP1MMP9 | |
| SCHEMBL28931721 | 0.85 | ALOX5 (0.48) | ALOX5MMP2CA2MMP1MMP9 | |
| SCHEMBL9815588 | 0.84 | CA2 (0.59) | MMP2CA2MMP1MMP9MMP13 | |
| SCHEMBL20047462 | 0.82 | PPARA (0.47) | ALOX5MMP2CA2MMP1MMP9 | |
| SCHEMBL18519523 | 0.82 | KMT2A (0.48) | ALOX5MMP2CA2MMP1MMP9 | |
| SCHEMBL497667 | 0.81 | NFKB1 (0.53) | MMP2CA2MMP1MMP9MMP13 | |
| SCHEMBL25339171 | 0.81 | MEN1 (0.52) | ALOX5MMP2CA2MMP1MMP9 | |
| SCHEMBL4946371 | 0.81 | KMT2A (0.68) | ALOX5MMP2CA2MMP1MMP9 | |
| SCHEMBL30191314 | 0.80 | MMP2 (0.50) | ALOX5MMP2CA2MMP1MMP9 | |
| SCHEMBL4432604 | 0.80 | EGFR (0.50) | ALOX5MMP2CA2MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109836360-B | Preparation method of edoxaban tosylate intermediate and intermediate compound | 南京恩泰医药科技有限公司 | 2021-08-13 | — | — | CN | claimed |
| CN-109836360-A | A kind of preparation method and midbody compound of toluenesulfonic acid Yi Dushaban intermediate | 南京恩泰医药科技有限公司 | 2019-06-04 | — | — | CN | claimed |
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2025-03-06 | — | — | US | disclosed |
| WO-2024256568-A1 | SALT AND CRYSTAL FORMS OF A MACROCYCLIC BTK INHIBITOR | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024245578-A1 | THERAPEUTIC COMBINATIONS OF AN IRREVERSIBLE BTK INHIBITOR AND A MACROCYCLIC REVERSIBLE BTK INHIBITOR | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V. (NL) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024246287-A1 | MEDICAL USE OF A MACROCYCLIC REVERSIBLE BTK INHIBITOR | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-12-05 | — | — | WO | disclosed |
| EP-4448523-A1 | MACROCYCLIC BTK INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448521-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| CN-118696041-A | Macrocyclic BTK inhibitors | 克罗斯费尔肿瘤学控股有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024126617-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-06-20 | — | — | WO | disclosed |
| CN-109836360-B | Preparation method of edoxaban tosylate intermediate and intermediate compound | 南京恩泰医药科技有限公司 | 2021-08-13 | — | — | CN | disclosed |
| CN-109836360-A | A kind of preparation method and midbody compound of toluenesulfonic acid Yi Dushaban intermediate | 南京恩泰医药科技有限公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-109836360-A | A kind of preparation method and midbody compound of toluenesulfonic acid Yi Dushaban intermediate | 南京恩泰医药科技有限公司 | 2019-06-04 | — | — | CN | disclosed |
| WO-2017156181-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017156181-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2151447-A1 | LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008076778-A1 | 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | ALOX5 1664/4885MMP2 632/4885CA2 4260/4885 |
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | BTK, LYN, LCK | ALOX5 3554/4885MMP2 4377/4885CA2 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.